Publications
Workpackage 1
Attanasio F., Cascio C., Fisichella S., Nicoletti V.G., Pignataro B., Savarino A. and Rizzarelli E. (2007) Trehalose effects on alpha-crystallin aggregates. Biochem Biophys. Res. Commun. 354, 899-905.
Bellotti V., NuvoloneM., Giorgetti S., Obici L., Palladini G., Russo P., Lavatelli F., Perfetti V., and Merlini G. (2007) The workings of the amyloid diseases. Ann. Med. 39, 200-207.
Buonomo R.P., Pappalardo G., Rizzarelli E., Santoro A.M., Tabbi G. and Vagliasindi L.I. (2007) Nitrogen oxide interaction with copper complexes formed by small peptides belonging to the prion protein octa-repeat region. Dalton Trans. 1400:8.
Fogolari F., Corazza A., Viglino P., Zuccato P., Pieri L., Faccioli P., Bellotti V. and Esposito G. (2007) Molecular Dynamics Simulation Suggests Possible Interaction Patterns at Early Steps of ß2-Microglobulin Aggregation. Biophys. J. 92, 1673-1681.
Giorgetti S., Stoppini M., Tennent G. A., Relini A., Marchese L., Raimondi S., Monti M., Marini S., Ostergaard O., Heegaard N H.H., Pucci P., Esposito G., Merlini G. and Bellotti V. (2007) Lysine58-cleaved ß2-microglobulin is not detectable by 2D electrophoresis in ex-vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Sci. 16, 343-349.
Giuffrida M.L., Grasso G., Ruvo M., Pedone C., Saporito A., Marasco D., Pignataro B., Cascio C., Copani A. and Rizzarelli E. (2007) Abeta(25-35) and its C- and/or N-blocked derivatives: copper driven structural features and neurotoxicity. J. Neurosci. Res. 85,623-633.
Picotti P, De Franceschi G, Frare E, Spolaore B, Zambonin M, Chiti F, Polverino de Laureto P and Fontana A (2007). Amyloid Fibril Formation and Disaggregation of Fragment 1-29 of Apomyoglobin: Insight into the Effect of pH on Protein Fibrillogenesis. J. Mol. Biol. 367, 1237-1245.
Workpackage 2
Enqvist S, Sletten K, Westermark P: Fibril protein fragmentation pattern in AL amyloidosis. J Pathol 2009;219:473-480
Workpackage 3
Suhr OB, Andersen O, Aronsson T, Jonasson J, Hellman U, Lundgren H-E, Melberg A, Nyberg J, Olsson M, Westermark P: Report of five rare or previously unknown amyloidogenic transthyretin mutations disclosed in Sweden. Amyloid 2009;16:208-214
Workpackage 4
Pokrzywa M, Dacklin I, Hultmark D, Lundgren E (2007). Misfolded TTR causes behavioral changes in a Drosophila model for transthyretin-associated amyloidosis. European J. Neuroscience 26: 913-924.
Workpackage 5
Enqvist S, Mellqvist UH, Mölne J, Sletten K, Murphy C, Solomon A, Stevens FJ, Westermark P: A father and his son with systemic AL amyloidosis. Haematologica 2009;94:437-439
Enqvist S, Sletten K, Stevens F, Westermark P: Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. PLoS ONE 2, e981, 2007
Ihse E, Stangou AJ,Heaton ND, O'Grady J, Ybo A, Hellman U, Edvinsson Å, Westermark P: Proportion of wild-type transthyretin in truncated compared to full-length TTR - an analysis on transplanted T60A amyloidosis patients. Biochem Biophys Res Commun 2009;379:846-850
Ihse E, Ybo A, Suhr OB, Lindqvist P, Backman C, Westermark P: Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Path 2008;216:253-261
Röcken C, Fändrich M, Stix B, Tannert A, Hortschansky P, Reinheckel T, Saftig P, Kähne T, Menard R, Ancsin JB, Bühling F. Cathepsin protease activity modulates amyloid-load in extracerebral amyloidosis. J Pathol. 2006 Dec;210(4):478-87
Solomon A, Macy SD, Wooliver C, Weiss DT, Westermark P: Splenic plasma cells can serve as a source of amyloidogenic light chains. Blood 2009;113:1501-1503
Solomon A, Richey T, Murphy CL, Weiss D, Wall JS, Westermark GT, Westermark P: Amyloidogenic potential of foie gras. Proc Natl Acad Sci USA 2007;104:10998-11001
Westermark GT, Westermark P: Serum amyloid A and protein AA: Molecular mechanims of a transmissible amyloidosis. FEBS Lett 2009;583:2685-2690
Westermark P: De systemiska amyloidoserna: ny behandling gör tidig och exakt diagnos allt viktigare. Läkartidningen, 104, 1517-1521, 2007 (Swedish)
Westermark P, Westermark GT: Reflections on amyloidosis in Papua New Guinea.
Philos Trans Royal Soc Lond B Biol Sci, 2008;363:3701-3705
Westermark P, Lundmark K, Westermark GT: Fibrils from designed non-amyloid-related synthetic peptides induce AA amyloidosis during inflammation in an animal model. PLoS ONE 2009;4:e6041
Workpackage 6
Altland K, Benson MD, Costello CE, Ferlini A, Hazenberg BP, Hund E, Kristen AV, Linke RP, Merlini G, Salvi F, Saraiva MJ, Singer R, Skinner M, Winter P. Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis. 2007; 28:2053-64.
Bellutti M, Weigt J, Mönkemüller K, Röcken C, Wieners G, Dombrowski F, Malfertheiner P (2007). Localized primary AL-type amyloidosis of the jejunum diagnosed by double-balloon enteroscopy. Endoscopy, Jul 9; [Epub ahead of print]
Bouma B, Maas C, Hazenberg BP, Lokhorst HM, Gebbink MF. Increased PAP levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost. 2007; 5:1139-42.
Daigeler A, Kuci H, Altmann S, Schneider W, Röcken C. Extramedullary multiple myeloma associated with amyloidomas of the lower limb. Plast Reconstr Surg. 2006;117:2530-2
Haagsma EB, van Gameren II, Bijzet J, Posthumus MD, Hazenberg BP. Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation. Amyloid 2007; 14:221-6.
Hazenberg BP. Diagnostic studies in amyloidosis [dissertation]. Groningen: University of Groningen, 2007.
Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, Livneh A, Lesnyak O, Nasonov EL, Filipowicz-Sosnowska A, Gül A, Merlini G, Wiland P, Özdogan H, Gorevic PD, Ben Maïz H, Benson MD, Direskeneli H, Kaarela K, Garceau D, Hauck W, van Rijswijk MH, on behalf of the Eprodisate For AA Amyloidosis Trial Group. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14:133-40.
Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, Jager PL. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med. 2007; 48:865-72.
Kebbel A, Röcken C. Immunohistochemical classification of amyloid revisited. Am J Surg Pathol. 2006;30:673-83
Kuci H, Ebert MPA, Röcken C. (2007) Peptide antibodies for the immunohistochemical classification of AL amyloid. Histol Histopathol. 22(4):379-87.
Meijer JM, Schonland SO, Palladini G, Merlini G, Hegenbart U, Ciocca O, Perfetti V, Leijsma MK, Bootsma H, Hazenberg BP. Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? Arthritis Rheum 2008 [in press].
Westermark GT, Sletten K, Westermark P: Alkali-degradation of amyloid: an ancient method useful for making monoclonal antibodies against amyloid fibril proteins. Scand J Immunol 2009;70:535-540
Workpackage 7
Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann H, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M, for the Eprodisate For AA Amyloidosis Trial Group. Eprodisate for the treatment of AA amyloidosis. N Engl J Med 2007; 356:2349-60.
Gales L, Almeida MR, Arsequell G, Valencia G, Saraiva MJ, Damas AM (2008). Iodination of salicylic acid improves its binding to transthyretin. Biochim Biophys Acta 1784/3 pp 512-517
Lokhorst HM, Hazenberg BP, Croockewit A. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [letter]. N Engl J Med. 2008; 358:92.
Suhr OB, Lundgren E, Westermark P: TTR-amyloidoses: new strategies for therapeutic intervention. Drugs of the Future 2010; in press
Verbeek DE, Hazenberg BP, Jager PL, Kremer Hovinga TD. [AL amyloidosis and the importance of precursor protein elimination.] Ned Tijdschr Geneeskd 2007; 151:2021-6 (Dutch).
Workpackage 8
Westermark P: Amyloidose-Zentren in Europa: Das EURAMY-Projekt. Pathologe 2009;30, Suppl 2:124-127 (German)